OnKure Therapeutics (OKUR) Stock: Buy, Sell, or Hold?
OKUR - OnKure Therapeutics, Inc. Class A Common Stock
$3.10
-0.17 (-5.20%)
▼
5d:
-12.92%
30d:
-21.12%
90d:
-27.06%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When OKUR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OKUR is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OKUR is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OKUR is currently trading at $3.10, which is considered oversold relative to its 30-day fair value range of $3.53 to $4.11.
Technical Outlook: Technically, OKUR is in a downtrend. Immediate support is located at $2.98, while resistance sits at $4.02. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: OKUR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+400.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OKUR is in a downtrend. Immediate support is located at $2.98, while resistance sits at $4.02. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: OKUR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+400.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.53 -
$4.11
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 400.0% below Wall St target ($15.50)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.53 -
$4.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.98
Resistance Level
$4.02
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.03
Wall Street Target
$15.50
(+400.0%)
Share & Embed Analysis
Last updated: September 12, 2026 2:36 PM ET
Data refreshes hourly during market hours. Next update: 3:36 PM
Data refreshes hourly during market hours. Next update: 3:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OKUR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason A Leverone
SELL
301 shares
2026-03-23
Nicholas A Saccomano
SELL
86 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
